No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
PHGE BiomX
- 0.2251
- -0.0699-23.69%
Close Jul 22 16:00 ET
- 0.2373
- +0.0122+5.42%
Post 16:45 ET
40.28MMarket Cap-381P/E (TTM)
0.3199High0.2230Low919.01KVolume0.3199Open0.2950Pre Close229.21KTurnover0.67%Turnover RatioLossP/E (Static)178.96MShares0.855052wk High-4.25P/B31.12MFloat Cap0.186652wk Low--Dividend TTM138.24MShs Float11.9000Historical High--Div YieldTTM32.85%Amplitude0.1320Historical Low0.2490Avg Price1Lot Size
Post-Market
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | Amex Halt Add Info Lst 0.234199
Cystic Fibrosis Market Is Projected to Boost by 2034, Predicts DelveInsight | Key Companies - Verona Pharmaceuticals, Vertex Pharmaceuticals, Krystal Biotech, Aridis Pharmaceuticals, BiomX, Inc., Boehringer Ingelheim
New York, USA, July 11, 2024 (GLOBE NEWSWIRE) -- Cystic Fibrosis Market is Projected to Boost by 2034, Predicts DelveInsight | Key Companies - Verona Pharmaceuticals, Vertex Pharmaceuticals, Krystal Biotech,
Express News | BiomX Discloses Stockholder Approval For Conversion Of Outstanding Series X Convertible Preferred Stock To Common Stock
Express News | Biomx Inc. Announces Stockholder Approval for Conversion of Outstanding Series X Convertible Preferred Stock to Common Stock
BiomX Shareholders Approve Expansion and Governance Changes
12 Health Care Stocks Moving In Tuesday's After-Market Session
GainersConcord Medical Services (NYSE:CCM) shares moved upwards by 131.0% to $4.85 during Tuesday's after-market session. The company's market cap stands at $210.6 million. Calidi Biotherapeutics (AME
Comments
$BiomX(PHGE.US$
BiomX to Present Phase 1b/2a Clinical Trial Data for BX004 at the 47th European Cystic Fibrosis Conference and at ASM Microbe 2024
The findings will be presented in an oral presentation and an ePoster at the 47th European Cystic Fibrosis Conference, which is taking place June 5-8, 2024, in Glasgow, United Kingdom, and in a Rapid Fire oral presentation and a poster at the American Society for Microbiology (ASM) Microbe 2024 meeting, being held June 13-1...
BiomX to Present Phase 1b/2a Clinical Trial Data for BX004 at the 47th European Cystic Fibrosis Conference and at ASM Microbe 2024
The findings will be presented in an oral presentation and an ePoster at the 47th European Cystic Fibrosis Conference, which is taking place June 5-8, 2024, in Glasgow, United Kingdom, and in a Rapid Fire oral presentation and a poster at the American Society for Microbiology (ASM) Microbe 2024 meeting, being held June 13-1...
$BiomX(PHGE.US$ BiomX Announces Closing Of The Acquisition Of Adaptive Phage Therapeutics And Concurrent $50 Million Financing
$BiomX(PHGE.US$ anybody in here hold till tomorrow?
2
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg